Investment Opportunity

Juva Life – The company set to help billions with inflammation issues

Juva Life Inc | Listed on: CSE:JUVA  |  OTCQB:JUVAF | JUVA.CN | JUVAF

Get report now
Share:

What is Juva Life?

.

On the surface, it might seem like Juva Life is simply an exciting operation taking advantage of the cannabis boom.

It has created a vertically integrated model that enables it to cultivate, manufacture and distribute the plant for retail purposes, any investor looking for good exposure to the growing sector would do well to put their money in the business.

But that’s not all the company has in its locker. Indeed, two recent discoveries by the company’s research and development team could have game-changing implications for the organization, its investors, and modern medicine in general.

The discoveries Juva Life has made could revolutionize the way we treat inflammation, which can cause health issues such as heart disease, diabetes, kidney troubles and cancer.

This is no surprise for chief executive Doug Chloupek. Since he founded Juva Life in 2018, it has always been his intention to move away from using cannabis to generate short-term retail profits and towards unlocking the plant’s more wide-ranging medicinal and therapeutic benefits.

The discoveries could hold the key to enormous returns for early investors and for Juva Life. This is because the anti-inflammation industry is growing and is expected to be worth over $117bn as soon as 2027.

Juva Life may have found the holy grail of anti-inflammation products! Access our full report on the company to find out more.

.

Why You Should Consider Investing

  • Revolutionary new discoveries

    Juva Life’s discovery of patented new molecules positioned to revolutionize the enormous market for anti-inflammatory products.

  • An accelerated and innovative approach

    Juva Life’s product development incurs a fraction of the cost, time, and risk of traditional clinical pathways.

  • The perfect operations team

    Juva Life’s operations led by a team of MJ visionaries, both on the business and scientific sides.

  • Ongoing Research & Development

    Juva Life’s product R&D funded by vertically integrated retail operations including cultivation and distribution facilities.

  • Targeted strategy

    Targeting large pharma takeout or key licensing agreements over medium term, opening the door to immense value creation.

  • Perfect time to invest

    The wider market has yet to catch on to the significance of major anti-inflammatory discoveries.

How It Works

.

The list of ailments cannabis is thought to be able to treat is growing with every passing day. At present, there is an established use of cannabis to address chronic pain, diabetes, anxiety, or any number of other problems.

 Companies like Juva Life who supply the wonder plant have enjoyed an onslaught of interest in recent years as more of us have sought it out as a potential solution. 

 However, there is a major problem for most cannabis suppliers. The tools are not readily available to measure the clinical effect and modes of action of the compounds contained within cannabis.

 In other words, there’s a lack of reproducible, clinical evidence around its health benefits.

 In the world of pharmaceuticals, regulators will only allow a product to be sold—and doctors will only recommend it to patients—once this evidence has been produced. What’s more, the existing clinical pathway to proving a medical product works and reaching the market, set out by bodies like the US Food and Drug Administration, is extremely arduous.

 But Juva Life was set up to overcome the research barriers that exist in today’s global market.

The company’s efforts are backed by an expert team of scientists including Guy Miller, who holds a PhD in chemistry, Sanjeev Gangwar, who holds over 40 patents in the pharmaceutical sciences, and Peter Beitch, the former president of the American Society of Breast Surgeons.

 Additionally, the company employs a product development pathway centered around IRB-approved longitudinal registry studies that incur a fraction of the cost, time, and risk of traditional product development efforts.

 This is how Juva Life plans to ensure that the right cannabis-derived products are delivered to the right individuals at the right time.

.

Research Breakthroughs

Since its launch, one of the key issues Juva Life has worked to address is the fact that an enormous amount of medical cannabis research and development currently focuses on cannabinoids like THC and CBD.

Juva Life acknowledges that cannabinoids can offer many potential health benefits through what is known as the “entourage effect”.

However, what the company is exploring is the idea that cannabis could contain other therapeutic, non-psychoactive compounds beyond cannabinoids like CBD that are also responsible for some of the plant’s health benefits.

Juva Life aims to establish whether these compounds could become even more effective when isolated and formulated into precision products by its scientists.

The company acknowledges that this is not an original idea, but previous attempts have been made by firms that didn’t boast Juva Life’s scientific pedigree, resources, and innovative approach to product development.

Juva’s work here has resulted in the ground-breaking discoveries known as JUVA-019 and JUVA-041. The duo are non-cannabinoid, purified small molecules isolated from cannabis that boasts broad-spectrum, anti-inflammatory properties. 

These products effectively have the potential to take any of the many health issues that are caused by chronic inflammation and cut them off at the source.

As such, the company has now entered the product development pathway for both JUVA-019 and JUVA-041, with a provisional patent already filed for the former.

Transformational Returns

The investment case for Juva Life is remarkably simple. Inflammation is a key driver of many of the world’s most serious diseases, and Juva Life has discovered two molecules that could fill a glaring gap in its treatment market.

This alone is reason enough to get excited about the company—especially when you consider its modest market cap at writing. But there’s a lot more to this story than the discovery of molecules alone.

Indeed, when you consider the team driving Juva Life, the unique, innovative R&D route the business is pursuing and the business’s established California-based recreational cannabis operations, it becomes clear that Juva Life has overcome most—if not all—of the typical barriers associated with start-up pharmaceutical companies.

If you want to know the endgame plan for Juva Life, click here to get a peek at our full report!

Get Report Now

Company Info

Founded by pioneers in the science and business of cannabis and guided by a team of highly-acclaimed medical professionals, Juva Life brings unprecedented depth of knowledge in the science and medicinal effects of cannabis.

Exchange / Symbol
CSE:JUVA
Market Capitalization
$ (usd)
Current price
$ (usd)
Current mid price
$ (usd)
52 Week high price
$ (usd)
52 Week low price
$ (usd)

Company Info

Founded by pioneers in the science and business of cannabis and guided by a team of highly-acclaimed medical professionals, Juva Life brings unprecedented depth of knowledge in the science and medicinal effects of cannabis.

Exchange / Symbol
OTCQB:JUVAF
Market Capitalization
$ (usd)
Current price
$ (usd)
Current mid price
$ (usd)
52 Week high price
$ (usd)
52 Week low price
$ (usd)

Juva Life is likely to generate huge interest over the coming weeks and months!

Check out our full report on the business to gain exciting insight.

IMPORTANT NOTICE AND DISCLAIMER

PAID ADVERTISEMENT

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Juva Life JL002 to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of two hundred and sixteen thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

CHANGES IN SHARE TRADING AND PRICE

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

NO OFFER TO SELL OR BUY SECURITIES

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.

INFORMATION

Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.

NO FINANCIAL ADVICE

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

FORWARD LOOKING STATEMENTS

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

TERMS OF USE AND DISCLAIMER

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.

INTELLECTUAL PROPERTY

All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.

AUTHORS: VALUETHEMARKETS

valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.